Skip to main content
TipRanks
Go Ultimate75% OFF

Allergy Therapeutics (AGYTF) Stock Statistics & Valuation Metrics

2 Followers

Total Valuation

Allergy Therapeutics has a market cap or net worth of $116.48M. The enterprise value is $478.24M.

Market Cap
$116.48M
Enterprise Value
$478.24M

Share Statistics

Allergy Therapeutics has 6,332,530,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
6,332,530,000
Owned by Insiders
―
Owned by Institutions
0.09%

Financial Efficiency

Allergy Therapeutics’s return on equity (ROE) is 4.97 and return on invested capital (ROIC) is -60.36%.

Return on Equity (ROE)
4.97
Return on Assets (ROA)
-0.59
Return on Invested Capital (ROIC)
-60.36%
Return on Capital Employed (ROCE)
-0.64
Revenue Per Employee
102.52K
Profits Per Employee
-88.20K
Employee Count
584
Asset Turnover
0.69
Inventory Turnover
2.24

Valuation Ratios

The current PE Ratio of Allergy Therapeutics is -1.59. Allergy Therapeutics’s PEG ratio is 0.18.

PE Ratio
-1.59
PS Ratio
1.48
PB Ratio
-8.53
Price to FCF
-2.39
Price to Operating Cash Flow
-2.75
PEG Ratio
0.18

Income Statement

In the last 12 months, Allergy Therapeutics had revenue of 59.87M and earned -51.51M in profits. Earnings per share was -0.01.

Revenue
59.87M
Gross Profit
24.78M
Operating Income
-40.98M
Pretax Income
-52.41M
Net Income
-51.51M
EBITDA
-36.34M
Earnings Per Share (EPS)
-0.01

Cash Flow

In the last 12 months, operating cash flow was -32.13M and capital expenditures -4.93M, giving a free cash flow of -37.06M billion.

Operating Cash Flow
-32.13M
Free Cash Flow
-37.06M
Free Cash Flow per Share
-0.01

Dividends & Yields

Allergy Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-41.81%
Earnings Yield
-58.23%

Stock Price Statistics

Beta
-2.13
52-Week Price Change
27.27%
50-Day Moving Average
0.15
200-Day Moving Average
0.14
Relative Strength Index (RSI)
0.28
Average Volume (3m)
―

Important Dates

Allergy Therapeutics upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 13, 2026
Next Earnings Date
Mar 04, 2027
Ex-Dividend Date
―

Financial Position

Allergy Therapeutics as a current ratio of 2.29, with Debt / Equity ratio of -646.31%

Current Ratio
2.29
Quick Ratio
1.61
Debt to Market Cap
0.15
Net Debt to EBITDA
-1.18
Interest Coverage Ratio
-5.02

Taxes

In the past 12 months, Allergy Therapeutics has paid -902.00K in taxes.

Income Tax
-902.00K
Effective Tax Rate
0.02

Enterprise Valuation

Allergy Therapeutics EV to EBITDA ratio is -3.62, with an EV/FCF ratio of -3.55.

EV to Sales
2.20
EV to EBITDA
-3.62
EV to Free Cash Flow
-3.55
EV to Operating Cash Flow
-4.09

Balance Sheet

Allergy Therapeutics has $24.20M in cash and marketable securities with $67.00M in debt, giving a net cash position of -$42.79M billion.

Cash & Marketable Securities
$24.20M
Total Debt
$67.00M
Net Cash
-$42.79M
Net Cash Per Share
-$0.01
Tangible Book Value Per Share
$0.00

Margins

Gross margin is 41.39%, with operating margin of -68.45%, and net profit margin of -86.04%.

Gross Margin
41.39%
Operating Margin
-68.45%
Pretax Margin
-83.62%
Net Profit Margin
-86.04%
EBITDA Margin
-60.70%
EBIT Margin
-68.45%

Analyst Forecast

The average price target for Allergy Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
12.84%
EPS Growth Forecast
-10.09%

Scores

Smart Score
4
AI Score
―